ID STF1_HUMAN Reviewed; 461 AA. AC Q13285; O15196; Q5T6F5; DT 15-JUL-1998, integrated into UniProtKB/Swiss-Prot. DT 01-JAN-1998, sequence version 2. DT 27-MAR-2024, entry version 240. DE RecName: Full=Steroidogenic factor 1; DE Short=SF-1; DE Short=STF-1; DE Short=hSF-1 {ECO:0000303|PubMed:8938589}; DE AltName: Full=Adrenal 4-binding protein; DE AltName: Full=Fushi tarazu factor homolog 1; DE AltName: Full=Nuclear receptor subfamily 5 group A member 1; DE AltName: Full=Steroid hormone receptor Ad4BP; GN Name=NR5A1; Synonyms=AD4BP, FTZF1, SF1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=8806624; DOI=10.1006/bbrc.1996.1343; RA Oba K., Yanase T., Nomura M., Morohashi K., Takayanagi R., Nawata H.; RT "Structural characterization of human Ad4bp (SF-1) gene."; RL Biochem. Biophys. Res. Commun. 226:261-267(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8938589; DOI=10.1677/jme.0.0170139; RA Wong M., Ramayya M.S., Chrousos G.P., Driggers P.H., Parker K.L.; RT "Cloning and sequence analysis of the human gene encoding steroidogenic RT factor 1."; RL J. Mol. Endocrinol. 17:139-147(1996). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Santa Barbara P., Desclozeaux M., Boizet B., Bonneaud N., Laudet V., RA Poulat F., Berta P.; RT "Cloning and characterization of the human steroidogenic factor 1 (SF-1) RT cDNA."; RL Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Pancreas, and Spleen; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 20-75. RA Yeh J.R., Chung B.C.; RT "Human SF1 genomic segment."; RL Submitted (JUL-1995) to the EMBL/GenBank/DDBJ databases. RN [8] RP TISSUE SPECIFICITY. RX PubMed=9177385; DOI=10.1210/jcem.82.6.3967; RA Ramayya M.S., Zhou J., Kino T., Segars J.H., Bondy C.A., Chrousos G.P.; RT "Steroidogenic factor 1 messenger ribonucleic acid expression in RT steroidogenic and nonsteroidogenic human tissues: Northern blot and in situ RT hybridization studies."; RL J. Clin. Endocrinol. Metab. 82:1799-1806(1997). RN [9] RP PHOSPHORYLATION AT SER-203. RX PubMed=10230405; DOI=10.1016/s1097-2765(00)80480-3; RA Hammer G.D., Krylova I., Zhang Y., Darimont B.D., Simpson K., Weigel N.L., RA Ingraham H.A.; RT "Phosphorylation of the nuclear receptor SF-1 modulates cofactor RT recruitment: integration of hormone signaling in reproduction and stress."; RL Mol. Cell 3:521-526(1999). RN [10] RP ACETYLATION AT LYS-34; LYS-38 AND LYS-72, AND SUBCELLULAR LOCATION. RX PubMed=11479297; DOI=10.1074/jbc.m104427200; RA Jacob A.L., Lund J., Martinez P., Hedin L.; RT "Acetylation of steroidogenic factor 1 protein regulates its RT transcriptional activity and recruits the coactivator GCN5."; RL J. Biol. Chem. 276:37659-37664(2001). RN [11] RP INTERACTION WITH SFPQ, AND IDENTIFICATION IN A COMPLEX WITH SFPQ AND NONO. RX PubMed=11897684; DOI=10.1210/endo.143.4.8748; RA Sewer M.B., Nguyen V.Q., Huang C.J., Tucker P.W., Kagawa N., Waterman M.R.; RT "Transcriptional activation of human CYP17 in H295R adrenocortical cells RT depends on complex formation among p54(nrb)/NonO, protein-associated RT splicing factor, and SF-1, a complex that also participates in repression RT of transcription."; RL Endocrinology 143:1280-1290(2002). RN [12] RP SUMOYLATION AT LYS-119 AND LYS-194, AND MUTAGENESIS OF LYS-119 AND LYS-194. RX PubMed=15192080; DOI=10.1210/me.2004-0173; RA Komatsu T., Mizusaki H., Mukai T., Ogawa H., Baba D., Shirakawa M., RA Hatakeyama S., Nakayama K.I., Yamamoto H., Kikuchi A., Morohashi K.; RT "Small ubiquitin-like modifier 1 (SUMO-1) modification of the synergy RT control motif of Ad4 binding protein/steroidogenic factor 1 (Ad4BP/SF-1) RT regulates synergistic transcription between Ad4BP/SF-1 and Sox9."; RL Mol. Endocrinol. 18:2451-2462(2004). RN [13] RP FUNCTION, AND INTERACTION WITH HIPK3. RX PubMed=17210646; DOI=10.1128/mcb.02253-06; RA Lan H.-C., Li H.-J., Lin G., Lai P.-Y., Chung B.-C.; RT "Cyclic AMP stimulates SF-1-dependent CYP11A1 expression through RT homeodomain-interacting protein kinase 3-mediated Jun N-terminal kinase and RT c-Jun phosphorylation."; RL Mol. Cell. Biol. 27:2027-2036(2007). RN [14] RP INTERACTION WITH DGKQ. RX PubMed=17664281; DOI=10.1128/mcb.00355-07; RA Li D., Urs A.N., Allegood J., Leon A., Merrill A.H. Jr., Sewer M.B.; RT "Cyclic AMP-stimulated interaction between steroidogenic factor 1 and RT diacylglycerol kinase theta facilitates induction of CYP17."; RL Mol. Cell. Biol. 27:6669-6685(2007). RN [15] RP PHOSPHORYLATION AT SER-203, AND INTERACTION WITH CDK7. RX PubMed=17901130; DOI=10.1210/me.2006-0478; RA Lewis A.E., Rusten M., Hoivik E.A., Vikse E.L., Hansson M.L., RA Wallberg A.E., Bakke M.; RT "Phosphorylation of steroidogenic factor 1 is mediated by cyclin-dependent RT kinase 7."; RL Mol. Endocrinol. 22:91-104(2008). RN [16] RP SUMOYLATION, AND PHOSPHORYLATION AT SER-203. RX PubMed=19015234; DOI=10.1128/mcb.00295-08; RA Yang W.-H., Heaton J.H., Brevig H., Mukherjee S., Iniguez-Lluhi J.A., RA Hammer G.D.; RT "SUMOylation inhibits SF-1 activity by reducing CDK7-mediated serine 203 RT phosphorylation."; RL Mol. Cell. Biol. 29:613-625(2009). RN [17] RP X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 222-461 IN COMPLEX WITH NCOA2 AND RP PHOSPHOLIPID. RX PubMed=15707893; DOI=10.1016/j.cell.2005.01.024; RA Krylova I.N., Sablin E.P., Moore J., Xu R.X., Waitt G.M., MacKay J.A., RA Juzumiene D., Bynum J.M., Madauss K., Montana V., Lebedeva L., Suzawa M., RA Williams J.D., Williams S.P., Guy R.K., Thornton J.W., Fletterick R.J., RA Willson T.M., Ingraham H.A.; RT "Structural analyses reveal phosphatidyl inositols as ligands for the NR5 RT orphan receptors SF-1 and LRH-1."; RL Cell 120:343-355(2005). RN [18] {ECO:0007744|PDB:1ZDT} RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 221-461 IN COMPLEX WITH NCOA2 AND RP A PHOSPHATIDYLETHANOLAMINE, AND MUTAGENESIS OF ALA-269; GLY-341; LEU-344; RP ALA-433; TYR-436 AND LYS-440. RX PubMed=15897460; DOI=10.1073/pnas.0409482102; RA Wang W., Zhang C., Marimuthu A., Krupka H.I., Tabrizizad M., Shelloe R., RA Mehra U., Eng K., Nguyen H., Settachatgul C., Powell B., Milburn M.V., RA West B.L.; RT "The crystal structures of human steroidogenic factor-1 and liver receptor RT homologue-1."; RL Proc. Natl. Acad. Sci. U.S.A. 102:7505-7510(2005). RN [19] RP VARIANT SRXY3 GLU-35. RX PubMed=10369247; DOI=10.1038/9629; RA Achermann J.C., Ito M., Ito M., Hindmarsh P.C., Jameson J.L.; RT "A mutation in the gene encoding steroidogenic factor-1 causes XY sex RT reversal and adrenal failure in humans."; RL Nat. Genet. 22:125-126(1999). RN [20] RP VARIANT AINR LEU-255. RX PubMed=11038323; DOI=10.1086/316893; RA Biason-Lauber A., Schoenle E.J.; RT "Apparently normal ovarian differentiation in a prepubertal girl with RT transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and RT adrenocortical insufficiency."; RL Am. J. Hum. Genet. 67:1563-1568(2000). RN [21] RP VARIANT SRXY3 GLN-92. RX PubMed=11932325; DOI=10.1210/jcem.87.4.8376; RA Achermann J.C., Ozisik G., Ito M., Orun U.A., Harmanci K., Gurakan B., RA Jameson J.L.; RT "Gonadal determination and adrenal development are regulated by the orphan RT nuclear receptor steroidogenic factor-1, in a dose-dependent manner."; RL J. Clin. Endocrinol. Metab. 87:1829-1833(2002). RN [22] RP VARIANTS SRXY3 MET-15; ILE-78; SER-91 AND GLN-437. RX PubMed=17200175; DOI=10.1210/jc.2006-1672; RA Lin L., Philibert P., Ferraz-de-Souza B., Kelberman D., Homfray T., RA Albanese A., Molini V., Sebire N.J., Einaudi S., Conway G.S., Hughes I.A., RA Jameson J.L., Sultan C., Dattani M.T., Achermann J.C.; RT "Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, RT NR5A1) are associated with 46,XY disorders of sex development with normal RT adrenal function."; RL J. Clin. Endocrinol. Metab. 92:991-999(2007). RN [23] RP VARIANTS SRXY3 SER-33 AND HIS-84, VARIANT ALA-146, AND CHARACTERIZATION OF RP VARIANTS SRXY3 SER-33 AND HIS-84. RX PubMed=17694559; DOI=10.1002/humu.20588; RA Koehler B., Lin L., Ferraz-de-Souza B., Wieacker P., Heidemann P., RA Schroeder V., Biebermann H., Schnabel D., Grueters A., Achermann J.C.; RT "Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY RT patients with severe underandrogenization but without adrenal RT insufficiency."; RL Hum. Mutat. 29:59-64(2008). RN [24] RP VARIANTS POF7 ALA-123; LEU-129; 231-LEU--LEU-233 DEL AND ASN-293, VARIANT RP ALA-146, AND CHARACTERIZATION OF VARIANTS POF7 ALA-123; LEU-129 AND RP ASN-293. RX PubMed=19246354; DOI=10.1056/nejmoa0806228; RA Lourenco D., Brauner R., Lin L., De Perdigo A., Weryha G., Muresan M., RA Boudjenah R., Guerra-Junior G., Maciel-Guerra A.T., Achermann J.C., RA McElreavey K., Bashamboo A.; RT "Mutations in NR5A1 associated with ovarian insufficiency."; RL N. Engl. J. Med. 360:1200-1210(2009). RN [25] RP VARIANTS SPGF8 ALA-123; LEU-129; LEU-131; CYS-191; SER-212 AND ASN-238, AND RP CHARACTERIZATION OF VARIANTS SPGF8 LEU-131; CYS-191; SER-212 AND ASN-238. RX PubMed=20887963; DOI=10.1016/j.ajhg.2010.09.009; RA Bashamboo A., Ferraz-de-Souza B., Lourenco D., Lin L., Sebire N.J., RA Montjean D., Bignon-Topalovic J., Mandelbaum J., Siffroi J.P., RA Christin-Maitre S., Radhakrishna U., Rouba H., Ravel C., Seeler J., RA Achermann J.C., McElreavey K.; RT "Human male infertility associated with mutations in NR5A1 encoding RT steroidogenic factor 1."; RL Am. J. Hum. Genet. 87:505-512(2010). RN [26] RP VARIANT SRXY3 TYR-65. RX PubMed=24405868; DOI=10.1186/1471-2350-15-7; RA Fabbri H.C., de Andrade J.G., Soardi F.C., de Calais F.L., Petroli R.J., RA Maciel-Guerra A.T., Guerra-Junior G., de Mello M.P.; RT "The novel p.Cys65Tyr mutation in NR5A1 gene in three 46,XY siblings with RT normal testosterone levels and their mother with primary ovarian RT insufficiency."; RL BMC Med. Genet. 15:7-7(2014). RN [27] RP VARIANT AINR GLN-92. RX PubMed=26523528; DOI=10.1210/jc.2015-3250; RA Guran T., Buonocore F., Saka N., Ozbek M.N., Aycan Z., Bereket A., Bas F., RA Darcan S., Bideci A., Guven A., Demir K., Akinci A., Buyukinan M., RA Aydin B.K., Turan S., Agladioglu S.Y., Atay Z., Abali Z.Y., Tarim O., RA Catli G., Yuksel B., Akcay T., Yildiz M., Ozen S., Doger E., Demirbilek H., RA Ucar A., Isik E., Ozhan B., Bolu S., Ozgen I.T., Suntharalingham J.P., RA Achermann J.C.; RT "Rare causes of primary adrenal insufficiency: genetic and clinical RT characterization of a large nationwide cohort."; RL J. Clin. Endocrinol. Metab. 101:284-292(2016). RN [28] RP VARIANT SRXX4 TRP-92, CHARACTERIZATION OF VARIANT SRXX4 TRP-92, INVOLVEMENT RP IN SRXX4, CHARACTERIZATION OF VARIANT SRXY3 GLN-92, AND SUBCELLULAR RP LOCATION. RX PubMed=27490115; DOI=10.1038/gim.2016.118; RA Baetens D., Stoop H., Peelman F., Todeschini A.L., Rosseel T., RA Coppieters F., Veitia R.A., Looijenga L.H., De Baere E., Cools M.; RT "NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular RT disorders of sex development."; RL Genet. Med. 19:367-376(2017). RN [29] RP INVOLVEMENT IN SRXX4, AND VARIANT SRXX4 GLN-92. RX PubMed=27855412; DOI=10.1159/000452888; RA Swartz J.M., Ciarlo R., Guo M.H., Abrha A., Weaver B., Diamond D.A., RA Chan Y.M., Hirschhorn J.N.; RT "A 46,XX ovotesticular disorder of sex development likely caused by a RT steroidogenic factor-1 (NR5A1) variant."; RL Horm. Res. Paediatr. 87:191-195(2017). RN [30] RP INVOLVEMENT IN SRXX4, INVOLVEMENT IN SRXY3, VARIANT SRXX4 TRP-92, VARIANT RP SRXY3 TRP-92, CHARACTERIZATION OF VARIANT SRXX4 TRP-92, AND FUNCTION. RX PubMed=27378692; DOI=10.1093/hmg/ddw186; RG Members of UDN; RA Bashamboo A., Donohoue P.A., Vilain E., Rojo S., Calvel P., RA Seneviratne S.N., Buonocore F., Barseghyan H., Bingham N., Rosenfeld J.A., RA Mulukutla S.N., Jain M., Burrage L., Dhar S., Balasubramanyam A., Lee B., RA Dumargne M.C., Eozenou C., Suntharalingham J.P., de Silva K., Lin L., RA Bignon-Topalovic J., Poulat F., Lagos C.F., McElreavey K., Achermann J.C.; RT "A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act RT as a molecular switch in human sex development."; RL Hum. Mol. Genet. 25:3446-3453(2016). RN [31] RP VARIANT SRXX4 TRP-92, CHARACTERIZATION OF VARIANT SRXX4 TRP-92, AND RP INVOLVEMENT IN SRXX4. RX PubMed=27610946; DOI=10.1002/humu.23116; RA Igarashi M., Takasawa K., Hakoda A., Kanno J., Takada S., Miyado M., RA Baba T., Morohashi K.I., Tajima T., Hata K., Nakabayashi K., Matsubara Y., RA Sekido R., Ogata T., Kashimada K., Fukami M.; RT "Identical NR5A1 missense mutations in two unrelated 46,XX individuals with RT testicular tissues."; RL Hum. Mutat. 38:39-42(2017). RN [32] RP VARIANTS SRXY3 18-ASP--GLY-22 DEL AND PRO-40, CHARACTERIZATION OF VARIANTS RP SRXY3 18-ASP--GLY-22 DEL AND PRO-40, AND FUNCTION. RX PubMed=28459839; DOI=10.1371/journal.pone.0176720; RA Werner R., Moenig I., Luenstedt R., Wuensch L., Thorns C., Reiz B., RA Krause A., Schwab K.O., Binder G., Holterhus P.M., Hiort O.; RT "New NR5A1 mutations and phenotypic variations of gonadal dysgenesis."; RL PLoS ONE 12:E0176720-E0176720(2017). CC -!- FUNCTION: Transcriptional activator. Essential for sexual CC differentiation and formation of the primary steroidogenic tissues CC (PubMed:27378692). Binds to the Ad4 site found in the promoter region CC of steroidogenic P450 genes such as CYP11A, CYP11B and CYP21B. Also CC regulates the AMH/Muellerian inhibiting substance gene as well as the CC AHCH and STAR genes. 5'-YCAAGGYC-3' and 5'-RRAGGTCA-3' are the CC consensus sequences for the recognition by NR5A1 (PubMed:27378692). The CC SFPQ-NONO-NR5A1 complex binds to the CYP17 promoter and regulates basal CC and cAMP-dependent transcriptional activity. Binds phosphatidylcholine CC (By similarity). Binds phospholipids with a phosphatidylinositol (PI) CC headgroup, in particular PI(3,4)P2 and PI(3,4,5)P3. Activated by the CC phosphorylation of NR5A1 by HIPK3 leading to increased steroidogenic CC gene expression upon cAMP signaling pathway stimulation. CC {ECO:0000250|UniProtKB:P33242, ECO:0000269|PubMed:17210646, CC ECO:0000269|PubMed:27378692, ECO:0000269|PubMed:28459839}. CC -!- SUBUNIT: Binds DNA as a monomer. Interacts with NR0B2 and PPARGC1A (By CC similarity). Part of a complex consisting of SFPQ, NONO and NR5A1. CC Interacts with NCOA2. Interacts with DGKQ and CDK7. Binds to and CC activated by HIPK3. {ECO:0000250|UniProtKB:P33242, CC ECO:0000269|PubMed:11897684, ECO:0000269|PubMed:15707893, CC ECO:0000269|PubMed:15897460, ECO:0000269|PubMed:17210646, CC ECO:0000269|PubMed:17664281, ECO:0000269|PubMed:17901130}. CC -!- INTERACTION: CC Q13285; Q13510: ASAH1; NbExp=4; IntAct=EBI-874629, EBI-714581; CC Q13285; Q13510-2: ASAH1; NbExp=3; IntAct=EBI-874629, EBI-21572613; CC Q13285; Q53TS8: C2CD6; NbExp=3; IntAct=EBI-874629, EBI-739879; CC Q13285; P61024: CKS1B; NbExp=3; IntAct=EBI-874629, EBI-456371; CC Q13285; O43639: NCK2; NbExp=3; IntAct=EBI-874629, EBI-713635; CC Q13285; P51843: NR0B1; NbExp=9; IntAct=EBI-874629, EBI-946109; CC Q13285; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-874629, EBI-741158; CC Q13285; P40937: RFC5; NbExp=3; IntAct=EBI-874629, EBI-712376; CC Q13285; Q8WW24: TEKT4; NbExp=3; IntAct=EBI-874629, EBI-750487; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407, CC ECO:0000269|PubMed:11479297, ECO:0000269|PubMed:27490115}. CC -!- TISSUE SPECIFICITY: High expressed in the adrenal cortex, the ovary, CC the testis, and the spleen (PubMed:9177385). CC {ECO:0000269|PubMed:9177385}. CC -!- PTM: Acetylation stimulates the transcriptional activity. CC {ECO:0000269|PubMed:11479297}. CC -!- PTM: Sumoylation reduces CDK7-mediated phosphorylation on Ser-203. CC {ECO:0000269|PubMed:15192080, ECO:0000269|PubMed:19015234}. CC -!- PTM: Phosphorylated on Ser-203 by CDK7. This phosphorylation promotes CC transcriptional activity. {ECO:0000269|PubMed:10230405, CC ECO:0000269|PubMed:17901130, ECO:0000269|PubMed:19015234}. CC -!- DISEASE: 46,XY sex reversal 3 (SRXY3) [MIM:612965]: A condition CC characterized by male-to-female sex reversal in the presence of a CC normal 46,XY karyotype. {ECO:0000269|PubMed:10369247, CC ECO:0000269|PubMed:11932325, ECO:0000269|PubMed:17200175, CC ECO:0000269|PubMed:17694559, ECO:0000269|PubMed:24405868, CC ECO:0000269|PubMed:27378692, ECO:0000269|PubMed:27490115, CC ECO:0000269|PubMed:28459839}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: 46,XX sex reversal 4 (SRXX4) [MIM:617480]: A condition in CC which male gonads develop in a genetic female (female to male sex CC reversal). {ECO:0000269|PubMed:27378692, ECO:0000269|PubMed:27490115, CC ECO:0000269|PubMed:27610946, ECO:0000269|PubMed:27855412}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Adrenal insufficiency, NR5A1-related (AINR) [MIM:612964]: A CC disorder characterized by adrenal insufficiency, muscular hypotonia, CC decreased sodium and increased potassium levels, elevated ACTH, salt- CC wasting crisis, prolonged jaundice, hypoglycemia, and vomiting. CC {ECO:0000269|PubMed:11038323, ECO:0000269|PubMed:26523528}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Premature ovarian failure 7 (POF7) [MIM:612964]: An ovarian CC disorder defined as the cessation of ovarian function under the age of CC 40 years. It is characterized by oligomenorrhea or amenorrhea, in the CC presence of elevated levels of serum gonadotropins and low estradiol. CC {ECO:0000269|PubMed:19246354}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Spermatogenic failure 8 (SPGF8) [MIM:613957]: An infertility CC disorder characterized by spermatogenesis failure and severe CC oligozoospermia. {ECO:0000269|PubMed:20887963}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR5 CC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D88155; BAA13546.1; -; Genomic_DNA. DR EMBL; U76388; AAB53105.1; -; mRNA. DR EMBL; AL137846; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL354979; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471090; EAW87591.1; -; Genomic_DNA. DR EMBL; BC032501; AAH32501.1; -; mRNA. DR EMBL; U32592; AAA75332.1; -; Genomic_DNA. DR CCDS; CCDS6856.1; -. DR PIR; JC4972; JC4972. DR RefSeq; NP_004950.2; NM_004959.4. DR RefSeq; XP_005251928.1; XM_005251871.3. DR RefSeq; XP_011516757.1; XM_011518455.2. DR PDB; 1YOW; X-ray; 3.00 A; A=222-461. DR PDB; 1ZDT; X-ray; 2.10 A; A/B=221-461. DR PDB; 4QJR; X-ray; 2.40 A; A=218-461. DR PDB; 4QK4; X-ray; 2.81 A; A=218-461. DR PDB; 7KHT; X-ray; 2.50 A; A=218-461. DR PDB; 8DAF; X-ray; 2.59 A; A/B=218-461. DR PDBsum; 1YOW; -. DR PDBsum; 1ZDT; -. DR PDBsum; 4QJR; -. DR PDBsum; 4QK4; -. DR PDBsum; 7KHT; -. DR PDBsum; 8DAF; -. DR AlphaFoldDB; Q13285; -. DR SMR; Q13285; -. DR BioGRID; 108792; 39. DR CORUM; Q13285; -. DR IntAct; Q13285; 44. DR MINT; Q13285; -. DR STRING; 9606.ENSP00000362690; -. DR BindingDB; Q13285; -. DR ChEMBL; CHEMBL4666; -. DR DrugBank; DB04683; (2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E)-OCTADEC-9-ENOATE. DR DrugBank; DB04752; Phosphatidyl ethanol. DR GuidetoPHARMACOLOGY; 632; -. DR GlyGen; Q13285; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q13285; -. DR PhosphoSitePlus; Q13285; -. DR BioMuta; NR5A1; -. DR DMDM; 3121738; -. DR MassIVE; Q13285; -. DR PaxDb; 9606-ENSP00000362690; -. DR PeptideAtlas; Q13285; -. DR ProteomicsDB; 59276; -. DR Antibodypedia; 16333; 517 antibodies from 35 providers. DR DNASU; 2516; -. DR Ensembl; ENST00000373588.9; ENSP00000362690.4; ENSG00000136931.10. DR GeneID; 2516; -. DR KEGG; hsa:2516; -. DR MANE-Select; ENST00000373588.9; ENSP00000362690.4; NM_004959.5; NP_004950.2. DR UCSC; uc004boo.2; human. DR AGR; HGNC:7983; -. DR CTD; 2516; -. DR DisGeNET; 2516; -. DR GeneCards; NR5A1; -. DR GeneReviews; NR5A1; -. DR HGNC; HGNC:7983; NR5A1. DR HPA; ENSG00000136931; Group enriched (adrenal gland, lymphoid tissue). DR MalaCards; NR5A1; -. DR MIM; 184757; gene. DR MIM; 612964; phenotype. DR MIM; 612965; phenotype. DR MIM; 613957; phenotype. DR MIM; 617480; phenotype. DR neXtProt; NX_Q13285; -. DR OpenTargets; ENSG00000136931; -. DR Orphanet; 243; 46,XX gonadal dysgenesis. DR Orphanet; 2138; 46,XX ovotesticular difference of sex development. DR Orphanet; 393; 46,XX testicular difference of sex development. DR Orphanet; 242; 46,XY complete gonadal dysgenesis. DR Orphanet; 251510; 46,XY partial gonadal dysgenesis. DR Orphanet; 399805; Male infertility with azoospermia or oligozoospermia due to single gene mutation. DR Orphanet; 619; NON RARE IN EUROPE: Primary ovarian failure. DR PharmGKB; PA31764; -. DR VEuPathDB; HostDB:ENSG00000136931; -. DR eggNOG; KOG4218; Eukaryota. DR GeneTree; ENSGT00940000153391; -. DR HOGENOM; CLU_011437_0_0_1; -. DR InParanoid; Q13285; -. DR OMA; EVTCNNL; -. DR OrthoDB; 2968690at2759; -. DR PhylomeDB; Q13285; -. DR TreeFam; TF350737; -. DR PathwayCommons; Q13285; -. DR Reactome; R-HSA-383280; Nuclear Receptor transcription pathway. DR Reactome; R-HSA-4090294; SUMOylation of intracellular receptors. DR Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells. DR Reactome; R-HSA-9690406; Transcriptional regulation of testis differentiation. DR SignaLink; Q13285; -. DR SIGNOR; Q13285; -. DR BioGRID-ORCS; 2516; 23 hits in 1177 CRISPR screens. DR EvolutionaryTrace; Q13285; -. DR GeneWiki; Steroidogenic_factor_1; -. DR GenomeRNAi; 2516; -. DR Pharos; Q13285; Tchem. DR PRO; PR:Q13285; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q13285; Protein. DR Bgee; ENSG00000136931; Expressed in right adrenal gland cortex and 65 other cell types or tissues. DR ExpressionAtlas; Q13285; baseline and differential. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISS:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; ISS:BHF-UCL. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0004879; F:nuclear receptor activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0005543; F:phospholipid binding; IDA:UniProtKB. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISS:BHF-UCL. DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:ParkinsonsUK-UCL. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0001221; F:transcription coregulator binding; IPI:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:InterPro. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0097720; P:calcineurin-mediated signaling; IEA:Ensembl. DR GO; GO:0008585; P:female gonad development; IMP:UniProtKB. DR GO; GO:0042445; P:hormone metabolic process; IEA:Ensembl. DR GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central. DR GO; GO:0033327; P:Leydig cell differentiation; IEA:Ensembl. DR GO; GO:0001553; P:luteinization; IEA:Ensembl. DR GO; GO:0051457; P:maintenance of protein location in nucleus; IEA:Ensembl. DR GO; GO:0008584; P:male gonad development; IMP:UniProtKB. DR GO; GO:0030238; P:male sex determination; IMP:BHF-UCL. DR GO; GO:2000195; P:negative regulation of female gonad development; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB. DR GO; GO:2000020; P:positive regulation of male gonad development; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:UniProtKB. DR GO; GO:0007538; P:primary sex determination; TAS:ProtInc. DR GO; GO:0050810; P:regulation of steroid biosynthetic process; TAS:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0097210; P:response to gonadotropin-releasing hormone; IEA:Ensembl. DR GO; GO:0060008; P:Sertoli cell differentiation; IEA:Ensembl. DR GO; GO:0007530; P:sex determination; IMP:UniProtKB. DR GO; GO:0009888; P:tissue development; IBA:GO_Central. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR CDD; cd07167; NR_DBD_Lrh-1_like; 1. DR CDD; cd07070; NR_LBD_SF-1; 1. DR Gene3D; 3.30.50.10; Erythroid Transcription Factor GATA-1, subunit A; 1. DR Gene3D; 1.10.565.10; Retinoid X Receptor; 1. DR IDEAL; IID00072; -. DR InterPro; IPR035500; NHR-like_dom_sf. DR InterPro; IPR016355; NR5-like. DR InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd. DR InterPro; IPR001723; Nuclear_hrmn_rcpt. DR InterPro; IPR001628; Znf_hrmn_rcpt. DR InterPro; IPR013088; Znf_NHR/GATA. DR PANTHER; PTHR24086; NUCLEAR RECEPTOR SUBFAMILY 5 GROUP A; 1. DR PANTHER; PTHR24086:SF24; STEROIDOGENIC FACTOR 1; 1. DR Pfam; PF00104; Hormone_recep; 1. DR Pfam; PF00105; zf-C4; 1. DR PIRSF; PIRSF002530; Nuc_orph_FTZ-F1; 1. DR PRINTS; PR00398; STRDHORMONER. DR PRINTS; PR00047; STROIDFINGER. DR SMART; SM00430; HOLI; 1. DR SMART; SM00399; ZnF_C4; 1. DR SUPFAM; SSF57716; Glucocorticoid receptor-like (DNA-binding domain); 1. DR SUPFAM; SSF48508; Nuclear receptor ligand-binding domain; 1. DR PROSITE; PS51843; NR_LBD; 1. DR PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1. DR PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1. DR Genevisible; Q13285; HS. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Activator; Disease variant; DNA-binding; KW Isopeptide bond; Lipid-binding; Metal-binding; Nucleus; Phosphoprotein; KW Premature ovarian failure; Receptor; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation; Zinc; Zinc-finger. FT CHAIN 1..461 FT /note="Steroidogenic factor 1" FT /id="PRO_0000053729" FT DOMAIN 222..459 FT /note="NR LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01189" FT DNA_BIND 10..85 FT /note="Nuclear receptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT ZN_FING 13..33 FT /note="NR C4-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT ZN_FING 49..73 FT /note="NR C4-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407" FT REGION 119..157 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 230..461 FT /note="Important for dimerization" FT COMPBIAS 124..143 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 341 FT /ligand="1,2-diacylglycero-3-phosphoethanolamine" FT /ligand_id="ChEBI:CHEBI:57613" FT /evidence="ECO:0000269|PubMed:15897460" FT BINDING 341 FT /ligand="a 1,2-diacyl-sn-glycero-3-phosphocholine" FT /ligand_id="ChEBI:CHEBI:57643" FT /evidence="ECO:0000250|UniProtKB:P33242" FT BINDING 436 FT /ligand="1,2-diacylglycero-3-phosphoethanolamine" FT /ligand_id="ChEBI:CHEBI:57613" FT /evidence="ECO:0000269|PubMed:15897460" FT BINDING 436 FT /ligand="a 1,2-diacyl-sn-glycero-3-phosphocholine" FT /ligand_id="ChEBI:CHEBI:57643" FT /evidence="ECO:0000250|UniProtKB:P33242" FT BINDING 440 FT /ligand="1,2-diacylglycero-3-phosphoethanolamine" FT /ligand_id="ChEBI:CHEBI:57613" FT /evidence="ECO:0000269|PubMed:15897460" FT BINDING 440 FT /ligand="a 1,2-diacyl-sn-glycero-3-phosphocholine" FT /ligand_id="ChEBI:CHEBI:57643" FT /evidence="ECO:0000250|UniProtKB:P33242" FT MOD_RES 34 FT /note="N6-acetyllysine" FT /evidence="ECO:0000305|PubMed:11479297" FT MOD_RES 38 FT /note="N6-acetyllysine" FT /evidence="ECO:0000305|PubMed:11479297" FT MOD_RES 72 FT /note="N6-acetyllysine" FT /evidence="ECO:0000305|PubMed:11479297" FT MOD_RES 203 FT /note="Phosphoserine; by CDK7" FT /evidence="ECO:0000269|PubMed:10230405, FT ECO:0000269|PubMed:17901130, ECO:0000269|PubMed:19015234" FT CROSSLNK 119 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:15192080" FT CROSSLNK 194 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO)" FT /evidence="ECO:0000269|PubMed:15192080" FT VARIANT 15 FT /note="V -> M (in SRXY3; without adrenal failure; FT dbSNP:rs104894124)" FT /evidence="ECO:0000269|PubMed:17200175" FT /id="VAR_063255" FT VARIANT 18..22 FT /note="Missing (in SRXY3; loss of DNA-binding; FT significantly decreased transactivator activity)" FT /evidence="ECO:0000269|PubMed:28459839" FT /id="VAR_079571" FT VARIANT 33 FT /note="C -> S (in SRXY3; without adrenal failure; markedly FT impaired transcriptional activity; dbSNP:rs1832496590)" FT /evidence="ECO:0000269|PubMed:17694559" FT /id="VAR_039106" FT VARIANT 35 FT /note="G -> E (in SRXY3; with adrenal failure; FT dbSNP:rs121918654)" FT /evidence="ECO:0000269|PubMed:10369247" FT /id="VAR_004737" FT VARIANT 40 FT /note="T -> P (in SRXY3; loss of DNA-binding; significantly FT decreased transactivator activity)" FT /evidence="ECO:0000269|PubMed:28459839" FT /id="VAR_079572" FT VARIANT 65 FT /note="C -> Y (in SRXY3; without adrenal failure)" FT /evidence="ECO:0000269|PubMed:24405868" FT /id="VAR_078136" FT VARIANT 78 FT /note="M -> I (in SRXY3; without adrenal failure; FT dbSNP:rs104894125)" FT /evidence="ECO:0000269|PubMed:17200175" FT /id="VAR_063256" FT VARIANT 84 FT /note="R -> H (in SRXY3; without adrenal failure; markedly FT impaired transcriptional activity; dbSNP:rs375469069)" FT /evidence="ECO:0000269|PubMed:17694559" FT /id="VAR_039107" FT VARIANT 91 FT /note="G -> S (in SRXY3; without adrenal failure; FT dbSNP:rs104894126)" FT /evidence="ECO:0000269|PubMed:17200175" FT /id="VAR_063257" FT VARIANT 92 FT /note="R -> Q (in SRXY3, SRXX4 and AINR; decreased FT transactivator activity; no effect on nuclear location; FT dbSNP:rs104894119)" FT /evidence="ECO:0000269|PubMed:11932325, FT ECO:0000269|PubMed:26523528, ECO:0000269|PubMed:27490115, FT ECO:0000269|PubMed:27855412" FT /id="VAR_016982" FT VARIANT 92 FT /note="R -> W (in SRXY3 and SRXX4; decreased transactivator FT activity; loss of DNA binding, at least to some known FT consensus target sequences; no effect on nuclear location; FT dbSNP:rs886039769)" FT /evidence="ECO:0000269|PubMed:27378692, FT ECO:0000269|PubMed:27490115, ECO:0000269|PubMed:27610946" FT /id="VAR_078137" FT VARIANT 123 FT /note="G -> A (in SPGF8 and POF7; activity levels similar FT to wild-type; dbSNP:rs200163795)" FT /evidence="ECO:0000269|PubMed:19246354, FT ECO:0000269|PubMed:20887963" FT /id="VAR_062967" FT VARIANT 129 FT /note="P -> L (in SPGF8 and POF7; loss of activity; FT dbSNP:rs200749741)" FT /evidence="ECO:0000269|PubMed:19246354, FT ECO:0000269|PubMed:20887963" FT /id="VAR_062968" FT VARIANT 131 FT /note="P -> L (in SPGF8; impairs transactivational FT activity; dbSNP:rs387906690)" FT /evidence="ECO:0000269|PubMed:20887963" FT /id="VAR_065866" FT VARIANT 146 FT /note="G -> A (in dbSNP:rs1110061)" FT /evidence="ECO:0000269|PubMed:17694559, FT ECO:0000269|PubMed:19246354" FT /id="VAR_039108" FT VARIANT 191 FT /note="R -> C (in SPGF8; impairs transactivational FT activity; dbSNP:rs1253324106)" FT /evidence="ECO:0000269|PubMed:20887963" FT /id="VAR_065867" FT VARIANT 212 FT /note="G -> S (in SPGF8; impairs transactivational FT activity; dbSNP:rs201095702)" FT /evidence="ECO:0000269|PubMed:20887963" FT /id="VAR_065868" FT VARIANT 231..233 FT /note="Missing (in POF7)" FT /evidence="ECO:0000269|PubMed:19246354" FT /id="VAR_062969" FT VARIANT 238 FT /note="D -> N (in SPGF8; impairs transactivational FT activity; dbSNP:rs780568525)" FT /evidence="ECO:0000269|PubMed:20887963" FT /id="VAR_065869" FT VARIANT 255 FT /note="R -> L (in AINR; dbSNP:rs104894118)" FT /evidence="ECO:0000269|PubMed:11038323" FT /id="VAR_016983" FT VARIANT 293 FT /note="D -> N (in POF7; without adrenal failure; partial FT loss of activity; dbSNP:rs121918655)" FT /evidence="ECO:0000269|PubMed:19246354" FT /id="VAR_062970" FT VARIANT 437 FT /note="L -> Q (in SRXY3; without adrenal failure; FT dbSNP:rs104894120)" FT /evidence="ECO:0000269|PubMed:17200175" FT /id="VAR_063258" FT MUTAGEN 119 FT /note="K->R: Loss of sumoylation; when associated with FT R-194." FT /evidence="ECO:0000269|PubMed:15192080" FT MUTAGEN 194 FT /note="K->R: Loss of sumoylation." FT /evidence="ECO:0000269|PubMed:15192080" FT MUTAGEN 269 FT /note="A->F: Strongly reduced transactivation." FT /evidence="ECO:0000269|PubMed:15897460" FT MUTAGEN 341 FT /note="G->E: Reduced transactivation. Strongly reduced FT transactivation; when associated with F-344." FT /evidence="ECO:0000269|PubMed:15897460" FT MUTAGEN 344 FT /note="L->F: Reduced transactivation. Strongly reduced FT transactivation; when associated with E-341." FT /evidence="ECO:0000269|PubMed:15897460" FT MUTAGEN 433 FT /note="A->F: Strongly reduced transactivation." FT /evidence="ECO:0000269|PubMed:15897460" FT MUTAGEN 436 FT /note="Y->F: Loss of transactivation; when associated with FT A-440." FT /evidence="ECO:0000269|PubMed:15897460" FT MUTAGEN 440 FT /note="K->A: Loss of transactivation; when associated with FT F-436." FT /evidence="ECO:0000269|PubMed:15897460" FT CONFLICT 63 FT /note="K -> N (in Ref. 1; BAA13546)" FT /evidence="ECO:0000305" FT HELIX 225..233 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 239..243 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 262..282 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 286..288 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 291..317 FT /evidence="ECO:0007829|PDB:1ZDT" FT STRAND 322..324 FT /evidence="ECO:0007829|PDB:1ZDT" FT STRAND 326..328 FT /evidence="ECO:0007829|PDB:1YOW" FT STRAND 330..332 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 333..339 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 342..360 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 365..376 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 381..383 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 387..408 FT /evidence="ECO:0007829|PDB:1ZDT" FT STRAND 411..413 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 415..442 FT /evidence="ECO:0007829|PDB:1ZDT" FT HELIX 451..456 FT /evidence="ECO:0007829|PDB:1ZDT" SQ SEQUENCE 461 AA; 51636 MW; 622644C62794826C CRC64; MDYSYDEDLD ELCPVCGDKV SGYHYGLLTC ESCKGFFKRT VQNNKHYTCT ESQSCKIDKT QRKRCPFCRF QKCLTVGMRL EAVRADRMRG GRNKFGPMYK RDRALKQQKK AQIRANGFKL ETGPPMGVPP PPPPAPDYVL PPSLHGPEPK GLAAGPPAGP LGDFGAPALP MAVPGAHGPL AGYLYPAFPG RAIKSEYPEP YASPPQPGLP YGYPEPFSGG PNVPELILQL LQLEPDEDQV RARILGCLQE PTKSRPDQPA AFGLLCRMAD QTFISIVDWA RRCMVFKELE VADQMTLLQN CWSELLVFDH IYRQVQHGKE GSILLVTGQE VELTTVATQA GSLLHSLVLR AQELVLQLLA LQLDRQEFVC LKFIILFSLD LKFLNNHILV KDAQEKANAA LLDYTLCHYP HCGDKFQQLL LCLVEVRALS MQAKEYLYHK HLGNEMPRNN LLIEMLQAKQ T //